



# Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,  
Worli, Mumbai - 400 030. India  
Tel. : + 91 22 6663 5456  
Fax : +91 22 6663 5460  
E-mail : auro@aurolabs.com  
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :  
K-56, M. I. D. C. Tarapur,  
Dist. Palghar, Maharashtra - 401506.  
CIN No. L33125MH1989PLC051910

**Date:** August 05, 2021.

To  
BSE Limited,  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**Reg: Security Code No. 530233:**

**Sub: Outcome of Board Meeting dated August 05, 2021**

Dear Sir,

Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today (i.e. **Thursday, August 05, 2021**), inter-alia, considered and approved the following matters:

**1. Un-audited Financial Results:**


The Un-audited Financial Results for the quarter ended June 30, 2021 as recommended by the Audit Committee.

In this regard, we are enclosing herewith:

- Un-audited Financial Results for the quarter ended June 30, 2021.
- Limited Review Report received from the Statutory Auditor of the Company.

**2. 32<sup>nd</sup> Annual General Meeting:**

The 32<sup>nd</sup> Annual General Meeting of the Company will be held on **Tuesday, August 31, 2021 at 11:30 a.m.** The Annual General Meeting shall be held by Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") in accordance with the



relevant Circulars issued by the Ministry of Corporate Affairs and SEBI to transact the business as contained in the Notice convening the AGM.


3. Based on the recommendations of Nomination and Remuneration Committee, the Board considered and approved the:
- i) Re-appointment Mr. Sharat Deorah as Chairman & Managing Director of the Company for a period of 3 years commencing from April 1, 2022, as the existing term expires on March 31, 2022 subject to approval of members.

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is as under:

**A brief Profile of Mr. Sharat Deorah**

Date of appointment and term of appointment	Date of re-appointment: 1 <sup>st</sup> April, 2022  Term of Re-appointment: - The Board of Directors of the Company have re-appointed Mr. Sharat Deorah as the Chairman & Managing Director for a term of 3 (Three) consecutive years commencing from April 1, 2022 till March 31, 2025 subject to approval of the members at the ensuing Annual General Meeting.
Reason for change	Re-appointment of Chairman & Managing Director
Brief Profile	Mr. Sharat Deorah is associated with the Company since May 26, 1989 as the Director of the Company and has an experience of over 34 years to his credit. He looks after the overall affairs of the Company including long term strategies.
Disclosure of relationships between directors	Mr. Sharat Deorah is the Father of Mr. Siddhartha Deorah

Mr. Sharat Deorah is not debarred from holding the office of Director by Virtue of any order passed by SEBI or any other such authority.



- ii) Re-appointment Mr. Siddhartha Deorah as Whole-Time Director of the Company for a period of 3 years commencing from April 1, 2022, as the existing term expires on March 31, 2022 subject to approval of members.

The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is as under:


**A brief Profile of Mr. Siddhartha Deorah**

Date of appointment and term of appointment	Date of re-appointment: 1 <sup>st</sup> April, 2022  Term of Appointment: - The Board of Directors of the Company have re-appointed Mr. Siddhartha Deorah as the Whole-time Director for a term of 3 (Three) consecutive years commencing from April 1, 2022 till March 31, 2025 subject to approval of the members at the ensuing Annual General Meeting.
Reason for change	Re-appointment of Whole-time Director
Brief Profile	Mr. Siddhartha Deorah is associated with the Company since August 01, 1999 as Director of the Company and has an experience of over 17 years in Production & Marketing. He looks after the Purchase and Sales aspects of the Company.
Disclosure of relationships between directors	Mr. Siddhartha Deorah is the Son of Mr. Sharat Deorah

Mr. Siddhartha Deorah is not debarred from holding the office of Director by Virtue of any order passed by SEBI or any other such authority.

**4. Appointment of M/s. Poddar & Co., Cost Auditors for the Financial Year 2021-22:**

Particulars	Cost Auditor
Name of the Firm	M/s. Poddar & Co., Cost Accountants
Address of the Firm	B-205, Chandulal Park, Station Road, Bhayandar (W), Thane - 401101.
Name of the Proprietor	Mr. Sandeep Poddar
Firm Registration No.	101734
Profile	The Firm is engaged in providing cost audit



	services
Term of Appointment	The Board of the Company has appointed the Firm for a term of one year w.e.f. April 1, 2021 till March 31, 2022

The meeting of the Board of Directors commenced at 3:00 PM and concluded at 4:15 PM. The results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 in due course.

Kindly take the above on your record.

Thanking You.

Yours faithfully,

For AURO LABORATORIES LIMITED

*Siddhartha Deorah*



**SIDDHARTHA DEORAH**  
**WHOLE TIME DIRECTOR**  
**[DIN: 00230796]**

**AURO LABORATORIES LIMITED**  
CIN NO. :- L33125MH1989PLC061910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR  
BOISAR, DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Website: www.aurolabs.com

**ANNEXURE - I**

<b>PART - I</b>		<b>(Rs. In Lakhs except EPS)</b>			
<b>STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2021</b>					
<b>Sr. No.</b>	<b>Particulars</b>	<b>3 Months ended</b>	<b>Preceding 3 Months ended</b>	<b>Corresponding 3 Months ended in the Previous Year</b>	<b>For the Year Ended</b>
		<b>30.06.2021</b>	<b>31.03.2021</b>	<b>30.06.2020</b>	<b>31.03.2021</b>
		<i>(Unaudited)</i>	<i>(Ref. Note 3)</i>	<i>(Unaudited)</i>	<i>(Audited)</i>
<b>1</b>	<b>Income from Operations</b>				
	(a) Net Sales/Income from Operations (Net of GST)	1,953.00	1,356.46	1,222.46	5,425.18
<b>2</b>	<b>Other Income</b>	49.54	17.17	5.69	75.78
<b>3</b>	<b>Total Revenue (1 + 2)</b>	1,102.54	1,373.63	1,228.15	5,500.96
<b>4</b>	<b>Expenses</b>				
	a. Consumption of raw material	779.27	518.36	737.19	2,743.09
	b. Purchase of Stock-in-trade	1.09	0.60	1.23	21.03
	c. (Increase) / decrease in Finished Goods stock in trade and work in progress	(158.71)	76.05	0.90	90.71
	d. Employee benefits expense	137.53	178.58	126.20	603.62
	e. Finance Cost	11.09	25.03	7.97	45.83
	f. Depreciation and amortisation expenses	26.00	27.56	25.00	103.56
	g. Other Expenses	155.80	278.18	138.46	842.58
	<b>Total Expenses (4)</b>	952.87	1,104.36	1,036.95	4,456.42
<b>5</b>	<b>Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)</b>	150.47	269.27	191.20	1,060.54
<b>6</b>	<b>Exceptional items</b>				
<b>7</b>	<b>Profit / (Loss) before extraordinary items and tax (5 ± 6)</b>	150.47	269.27	191.20	1,060.54
<b>8</b>	<b>Extraordinary items</b>	-		-	
<b>9</b>	<b>Profit / (Loss) before tax (7 ± 8)</b>	150.47	269.27	191.20	1,060.54
<b>10</b>	<b>Tax expense</b>				
	(a) Current tax expenses for current year	43.82	104.91	52.58	320.09
	(b) MAT credit (where applicable)	-		-	
	(c) Defferered tax	-	12.49	-	12.49
<b>11</b>	<b>Profit / (Loss) for the period from continuing operation (9± 10)</b>	106.65	151.87	138.62	717.96
<b>12</b>	<b>Profit / (Loss) for discontinuing operations</b>	-		-	
<b>13</b>	<b>Tax expense of discontinuing operations</b>				
<b>14</b>	<b>Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)</b>	106.65	151.87	138.62	717.96
<b>15</b>	<b>Other Comprehensive Income</b>	8.53	1.76	7.69	1.76
<b>16</b>	<b>Total Comprehensive Income for the period (14 ± 15)</b>	115.18	153.63	146.31	719.72
<b>17</b>	<b>Paid-up equity share capital</b>	623.25	623.25	623.25	623.25
	(Face value of Rs. 10 each) *				
<b>18</b>	<b>Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year)</b>	-		-	2,235.01
<b>19</b>	<b>Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):</b>				
	(a) Basic	1.71	2.44	2.22	11.52
	(b) Diluted	1.71	2.44	2.22	11.52

**Notes:**

- 1) The above unaudited financial results for the quarter ended 30th June, 2021 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 5th August 2021.
- 2) The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) Figures for the quarter ended March 31, 2021 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures of nine months ended December 31, 2020.
- 5) Limited review has been carried out by the Statutory Auditors of the Company.
- 6) Figures of previous period have regrouped / reclassified wherever necessary to facilitate comparison.

FOR & BEHALF OF THE BOARD OF DIRECTORS  
AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH  
WHOLE TIME DIRECTOR  
DIN NO. 00230796



Place : Mumbai  
Date : 05.08.2021



**KHURDIA JAIN & CO.**  
CHARTERED ACCOUNTANTS

To,  
The Board of Directors,  
Auro Laboratories Limited.

We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the Quarter ended June 30, 2021, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.

This Statement is the responsibility of the Company's Management and had been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act 2013 read with relevant rules issued thereunder and accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Khurdia Jain & Co.  
Chartered Accountants

*Sampat Khurdia*



Sampat Khurdia  
Partner  
Membership No. 033615  
Firm Reg. No. 120263W  
Place: Mumbai  
Date: 5<sup>th</sup> August 2021  
UDIN : 21033615AAAADL1131